Description:
In Vitro Diagnostics (IVD) in Malaysia, Singapore and Indonesia, 2022 by Kalorama Information presents a comprehensive market research report focusing on the burgeoning IVD market in Southeast Asia. As part of the fast-growing Asia Pacific (APAC) region, Southeast Asia offers significant opportunities for IVD companies, with Malaysia, Indonesia, and Singapore at the forefront.
Report Highlights:
- Malaysia: With a population of about 32 million, Malaysia offers a balanced market for IVD companies, boasting growing healthcare service capabilities and promising growth potential.
- Singapore: Despite its smaller population of less than 6 million, Singapore’s advanced healthcare infrastructure and skilled workforce make it a lucrative market for IVD companies. Known as a medical tourism hub, Singapore provides world-class healthcare services.
- Indonesia: Home to approximately 275 million people, Indonesia presents vast opportunities for IVD companies. The country is actively enhancing its healthcare infrastructure, making it a key market in the region.
Segments Covered:
- Point-of-Care Testing (POC)
- Clinical Chemistry
- Immunoassays
- Molecular Assays
- Hematology
- Coagulation
- Microbiology and Virology
- Blood Testing and Typing
- Histology and Cytology
This report provides an in-depth analysis of the IVD markets in these three countries, highlighting the unique opportunities and challenges within each market. It also offers valuable insights into population demographics, healthcare infrastructure, and market trends, making it an essential resource for any IVD company looking to expand in Southeast Asia.
For further details and to purchase directly, please contact us.
Sample Report: A sample is available as a PDF upon request.
Table: Malaysia’s IVD Market, by Segment, 2022-2027 ($ Millions)
| Test Type | 2022 | 2027 | CAGR |
| POC | $XX Million | $XX Million | XX% |
| Clinical Chemistry | $XX Million | $XX Million | XX% |
| Immunoassays | $XX Million | $XX Million | XX% |
| Molecular Assays | $XX Million | $XX Million | XX% |
| Hematology | $XX Million | $XX Million | XX% |
| Coagulation | $XX Million | $XX Million | XX% |
| Microbiology and Virology | $XX Million | $XX Million | XX% |
| Blood Testing and Typing | $XX Million | $XX Million | XX% |
| Histology and Cytology | $XX Million | $XX Million | XX% |
| Total | $XX Million | $XX Million | XX% |
Source: Kalorama Information
